Polyomavirus-associated nephropathy

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 6

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

499

HTML

3665

Tables (1-4)

187

Sum=4351

Dec 24, 2012 (publication date) through Nov 18, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Transplant. Dec 24, 2012; 2(6): 84-94
Published online Dec 24, 2012. doi: 10.5500/wjt.v2.i6.84

Table 4 Recommended treatment of polyomavirus-associated nephropathy by reduction or switching of immunosuppression[49]

Switching	Decreasing
Tacrolimus → Cyclosporine A (trough levels 100-150 ng/mL)	Tacrolimus (trough levels < 6 ng/mL)
Mycophenolate mofetil → Azathioprine (dose ≤ 100 mg/d)	Cyclosporine A (trough levels 100-150 ng/mL)
Tacrolimus → sirolimus (trough levels < 6 ng/mL)	Mycophenolate mofetil dose ≤ 1 g/d
Mycophenolate mofetil → sirolimus (trough levels < 6 ng/mL)	Cyclosporine A (trough levels 100-150 ng/mL)
Mycophenolate mofetil → leflunomide

Citation: Costa C, Cavallo R. Polyomavirus-associated nephropathy. World J Transplant 2012; 2(6): 84-94
URL: https://www.wjgnet.com/2220-3230/full/v2/i6/84.htm
DOI: https://dx.doi.org/10.5500/wjt.v2.i6.84